ArriVent
AVBPArriVent BioPharma, Inc. Common Stock Price (AVBP)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
31,956,657
(4.5892)%
Community Sentiment
0 votes
↑ 0%
↓ 0%
Description
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR... Read More
Sector: Healthcare
- Previous Close Fetching Data...
- Range $14.35-36.37
- Market Cap 663.32M
- Enterprise Value No Data
- Avg Volume Fetching Data...
- P/E Ratio Fetching Data...
- Dividend Yield Fetching Data...
Industry: Biotechnology
- ceo: Dr. Zhengbin Yao Ph.D.
- IPO Date: January, 26, 2024
- Country: US
- Currency: USD
- Headquaters: No Data
- Employees: 52
- Revenue from each product or segment:
| Product or Segment | Value: | % - Total | Last 3Y: |
|---|
- Revenue by Region
| Product or Segment | Value: | % - Total | Last 3Y: |
|---|